Wednesday - ARVO

Wednesday – Posters – 5050 – 5074
5050 — B0008 Design of a Non-Invasive Coreshell
Nanoparticulate Drug Delivery System for
Posterior Part of the Eye. Binapani Mahaling, D.
S. Katti. Biological Sciences and Bioengineering,
Indian Institute of Technology Kanpur, Kanpur,
India
5051 — B0009 Development and
characterization of silicone pressure sensitive
adhesive episcleral implant. He Wen, S. Li.
University of Cincinnati, Cincinnati, OH *CR
5052 — B0010 Ocular injection characteristics
and in vitro release profiles of lipophilic dye
using thermogel PLGA-PE-PLGA as a sustainedrelease
drug delivery device. Eva Abarca, P. M.
Potter, J. H. Salmon, B. C. Gilger. North Carolina
State University, Raleigh, NC *CR
5053 — B0011 Development of Aqueous
Nanomicellar Formulation for Topical Delivery
of Biotinylated Lipid Prodrug of Acyclovir to
Treat Herpetic Keratitis. Aswani Dutt Vadlapudi,
K. Cholkar, R. Vadlapatla, A. K. Mitra. Division of
Pharmaceutical Sciences, University of Missouri-
Kansas City, Kansas City, MO
5054 — B0012 Dexamethasone Sustained
Delivery From Polyesteramide Microspheres
For Intraocular Administration. Influence
Of Sterilization. Vanessa Andres-Guerrero 1 , M.
Zong 2 , G. Mihov 2 , A. A. Dias 2 , R. Herrero-Vanrell 1 .
1
Pharmaceutical Technology, Faculty of Pharmacy/
Complutense University, Madrid, Spain; 2 DSM,
Geleen, Netherlands *CR
5055 — B0013 Pharmacodynamic study
of Intravitreal liposomal doxorubicin by
matrix-assisted laser desorption/ionizationmass
spectrometry (MALDI/MS). Hsi-Kung
Kuo, Y. Chen, P. Wu. Ophthalmology, Kaohsiung
Chang Gung Memorial Hospital and Chang Gung
University College of Medicine, Kaohsiung, Taiwan
5056 — B0014 Cavernous Sinus as Ocular
Pharmacokinetic Compartment for Better
Understanding of Posterior Segment and
Contralateral Eye Drug Availability. Muhammad
Abdulrazik. Ophthal/Innovative Interventions, East
Jerusalem Biomedical Institute, East Jerusalem,
Occupied Palestinian Territory
5057 — B0015 Influence of Physicochemical
Properties on Drug Delivery across Sclera into
Choroid-Retina. Ayumi Yoshimatsu 1 , C. Yabuta 1 ,
A. Ohtori 1, 2 , M. Azuma 1 . 1 Senju Laboratory of
Ocular Sciences, Senju Pharmaceutical Co., Ltd.,
Kobe, Japan; 2 Laboratory of Ocular Drug Delivery
System, Kyushu Institute of Technology, Fukuoka,
Japan *CR
5058 — B0016 Sustained Prednisolone
Acetate-loaded Microfilm Drug Delivery System
Effectively Prolongs corneal allograft survival
in the rat keratoplasty model. Yu-Chi Liu 1, 2 , Y.
Peng 3 , N. Lwin 1 , S. Venkatraman 3 , T. Wong 1, 2 , J.
S. Mehta 1, 2 . 1 Singapore Eye Research Institute,
Singapore, Singapore; 2 Singapore National Eye
Centre, Singapore, Singapore; 3 School of Materials
Science and Engineering, Nanyang Technological
University, Singapore, Singapore *CR
5059 — B0017 Treatment of Acute Posterior
Uveitis by Injection of Triamcinolone
Acetonide into the Suprachoroidal Space Using
Microneedles. Brian C. Gilger 1 , E. M. Abarca 1 , J.
H. Salmon 1 , S. R. Patel 2 . 1 Clinical Sciences, North
Carolina State University, Raleigh, NC; 2 Clearside
Biomedical, Alpharetta, GA *CR
5060 — B0018 Ocular and Systemic
Pharmacokinetics of a PDE4 Inhibitor Following
Topical Administration (Eyedrop) in Male
Dutch-Belted Rabbits. David C. Gale 1 , C. J.
Sychterz 2 , C. Rodgers 2 , S. Wang 2 , T. Wilde 2 , A.
Krishnatry 2 , H. Ellens 2 . 1 Ophthalmology DPU,
GlaxoSmithKline, King of Prussia, PA; 2 PTS
DMPK-UM, GlaxoSmithKline, King of Prussia,
PA *CR
5061 — B0019 Aqueous humor concentration
of Bromfenac 0.09% (Bromday) compared with
Bromfenac in DuraSite 0.075% (Bromsite) in
cataract patients undergoing phacoemulsification
after 3 days dosing. Kamran Hosseini 1 , J.
Hutcheson 1 , L. M. Bowman 2 . 1 Clinical, InSite Vision
Inc, Alameda, CA; 2 Development, InSite Vision,
Alameda, CA *CR, f
5062 — B0020 Comparison of the Total
Amount of Triamcinolone Acetonide
Delivered Via Suprachoroidal or Intravitreal
Administration. Brian Burke, R. S. Verhoeven, S.
R. Patel. Clearside Biomedical, Raleigh, NC *CR
5063 — B0021 Suprachoroidal Microinjection
Delivers Triamcinolone Acetonide to
Therapeutically-Relevant Posterior Ocular
Structures and Limits Exposure in the Anterior
Segment. Henry F. Edelhauser 1, 2 , S. R. Patel 2 , C.
Meschter 3 , R. Dean 3 , K. Powell 4 , R. S. Verhoeven 2 .
1
Ophthalmology, Emory Univ Eye Center,
Atlanta, GA; 2 Clearside Biomedical, Alpharetta,
GA; 3 Comparative Biosciences, Sunnyvale, CA;
4
Tandem Labs, Durham, NC *CR
5064 — B0022 Protective Effects of
Transscleral Drug Delivery Device Against
Photoreceptor Cell Death in S334ter Rhodopsin
Mutant Rats. Nobuhiro Nagai 1 , H. Kaji 2 , H.
Onami 1 , T. Yamada 2 , Y. Katsukura 1 , Y. Ishikawa 1 ,
M. Nishizawa 2 , Y. Mashima 3 , T. Abe 1 . 1 Graduate
School of Medicine, Tohoku University, Sendai,
Japan; 2 Graduate School of Engineering, Tohoku
University, Sendai, Japan; 3 R-Tech Ueno, Tokyo,
Japan *CR
5065 — B0023 In vitro cytotoxicity screening
and pharmacokinetic modeling: a tool in the
development of ocular drug delivery systems.
Eva Tuominen 1 , G. Mihov 2 , M. Zong 2 , S. Sarkhel 1 ,
A. A. Dias 2 , A. Urtti 1 . 1 Centre for Drug Research,
Faculty of Pharmacy, University of Helsinki,
Helsinki, Finland; 2 DSM, Geleen, Netherlands *CR
5066 — B0024 Retinal Safety and Efficacy of
a Dexamethasone Biodegradable Implant to
Treat Macular Edema Associated to Retinal Vein
Occlusion: A Phase I/II Clinical Trial. Rubens C.
Siqueira 1 , R. B. Cunha 1 , A. Messias 1 , A. S. Cunha 2 ,
S. Fialho 2 , R. Jorge 1 . 1 Retina, Sao Paulo University,
Sao Jose do Rio Preto, Brazil; 2 Pharmacology,
Minas Gerais Federal University, Belo Horizonte,
Brazil f
5067 — B0025 Therapeutic effect of
stealth-type polymeric nanoparticles with
encapsulated cyclosporine A on experimental
autoimmune uveoretinitis. Tsutomu Sakai 1 , K.
Kuroyanagi 1 , T. Ishihara 2 , K. Okano 1 , H. Tsuneoka 1 .
1
Ophthalmology, Jikei Univ School of Medicine,
Setagaya-ku, Japan; 2 Chemical biology and applied
chemistry, Nihon university college of engineering,
Kooriyama, Japan
5068 — B0026 Development of an in vitro
pharmacokinetic model of the human eye.
Sahar Awwad 1, 2 , A. Lockwood 1, 2 , A. Mohamed
Ahmed 1, 2 , G. Sharma 1, 2 , A. Khalili 2 , S. Brocchini 1, 2 ,
P. T. Khaw 2 . 1 UCL School of Pharmacy, London,
United Kingdom; 2 National Institute for Health
Research (NIHR) Biomedical Research Centre at
Moorfields Eye Hospital NHS Foundation Trust and
UCL Institute of Ophthalmology, London, United
Kingdom *CR
5069 — B0027 Tunable sustained intravitreal
drug delivery system for daunorubicin using
oxidized porous silicon. Huiyuan Hou 1 , A.
Nieto 2 , F. Ma 1 , S. Lee 1 , K. Nan 1 , W. R. Freeman 1 ,
M. J. Sailor 2, 3 , L. Cheng 1 . 1 Department of
Ophthalmology, Shiley Eye Center, UCSD,
San Diego, CA; 2 Department of Chemistry and
Biochemistry, UCSD, San Diego, CA; 3 Department
of Bioengineering, UCSD, San Diego, CA *CR
5070 — B0028 3D Computational Fluid
Dynamic Simulation of an Intravitreal
Brimonidine Implant in the Rabbit Eye. Julie
E. Whitcomb 1 , S. S. Lee 2 , B. D. Swift 1 , J. Rowe 3 ,
M. R. Kazemi 4 , J. Shen 1 . 1 Pharmacokinetics
& Drug Disposition, Allergan, Irvine, CA;
2
Ophthalmology Clinical Research, Allergan, Irvine,
CA; 3 Bioanalytical Sciences, Allergan, Irvine, CA;
4
Independent Engineer Consultant, San Jose, CA
*CR
5071 — B0029 Optimization of In-vitro
DiffER model to study/compare the effect
of Formulations on Cross-Scleral transport
of poorly aqueous soluble drug. Thomas E.
Rowe 1 , K. W. Reed 2, 1 , T. Bhowmik 1 . 1 Encompass
Pharmaceutical Services, Norcross, GA;
2
Pharmaceutical Sciences, Belmont University,
Nashville, TN *CR
5072 — B0030 Ocular bioavailability of
brimonidine 0.1% BID in non-human primates.
Chinatsu Tosha, S. Decker, G. Ruiz, O. Avalos, W.
Orilla, L. Gruber, T. Lin, A. S. Almazan, D. W. Gil,
J. A. Burke. Biological Science, Allergan, Inc.,
Irvine, CA *CR
5073 — B0031 Sustained Delivery of
Prostaglandin from Drug-Containing Depots
Using Ocular Rings in Beagles. Kathryn S.
Crawford 1 , J. Y. Ellis 2 , J. Rulander 3 , S. Johnston 3 ,
F. S. Lai 3 , E. J. Ellis 2 , C. D. Leahy 2 . 1 PharmOcu,
Andover, MA; 2 Vista Scientific, LLC, Andover,
MA; 3 Massachusetts Medical Device Development
Center, University of Massachusetts, Lowell, MA
*CR
5074 — B0032 Evaluating & Predicting Drug
Release from an Implantable Biomaterial. Ivana
Postic, H. Sheardown. Chemical Engineering,
McMaster University, Hamilton, ON, Canada *CR
Wednesday Posters
2:45 pm – 4:30 pm
f Refer to the Program Number in the Clinical Trial (CT) Registration Index. *CR Refer to the Program Number in the Commercial Relationships (CR) Index for Disclosures.
325